Loading
A phase 2 trial of Orca-T in myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., now recruiting.
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 2 interventional study registered as NCT07216443 by Orca Biosystems, Inc., with 80 participants planned, started 2025-12-09 and due to reach its primary completion in 2027-11. Interventions recorded: Orca-T.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Orca Bio, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.